Literature DB >> 24510631

Who would really benefit from DPP-4 inhibitors?

Nasser Mikhail1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24510631     DOI： 10.1007/s12020-014-0189-y

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  7 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 3.  Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients.

Authors:  Katherine Esposito; Paolo Chiodini; Annalisa Capuano; Maria Ida Maiorino; Giuseppe Bellastella; Dario Giugliano
Journal:  Endocrine       Date:  2013-11-20       Impact factor: 3.633

4.  The metabolic syndrome influences the response to incretin-based therapies.

Authors:  Gian Paolo Fadini; Saula Vigili de Kreutzenberg; Romelda Gjini; Angelo Avogaro
Journal:  Acta Diabetol       Date:  2011-05-15       Impact factor: 4.280

5.  Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.

Authors:  Yoshimasa Aso; Noriyuki Ozeki; Tomoko Terasawa; Rika Naruse; Kenji Hara; Mariko Suetsugu; Kohzo Takebayashi; Mitsuei Shibazaki; Kohsuke Haruki; Kimio Morita; Toshihiko Inukai
Journal:  Transl Res       Date:  2011-10-17       Impact factor: 7.012

6.  Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.

Authors:  Matteo Monami; Francesco Cremasco; Caterina Lamanna; Niccolò Marchionni; Edoardo Mannucci
Journal:  Diabetes Metab Res Rev       Date:  2011-05       Impact factor: 4.876

Review 7.  Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.

Authors:  Nasser Mikhail
Journal:  Postgrad Med       Date:  2012-07       Impact factor: 3.840
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.